Regulatory Approval

As the EU's strict new packaging laws loom, a Shanghai lab offers a vital lifeline for Asia-Pacific exporters, turning a complex compliance hurdle into an innovation race.

Merlin's new design authority from New Zealand isn't just a certificate; it's a strategic move that could reshape the path to commercial autonomous flight.

FDA clearance for Roche's pTau217 blood test isn't just a clinical win; it's a strategic move to dominate a $27B market by making diagnosis simple and scalable.

Takeda's ORZEYFUL, a first-in-class orexin agonist, wins approval in Japan, offering the first treatment for the root cause of Narcolepsy Type 1.

Marking its 10th year, Solowin Holdings secured a landmark Bahrain stablecoin license, pioneering a compliance-first model for the AI and digital asset era.

E-Power's joint venture is poised for elite 'Little Giant' status in China, a move validating its advanced battery materials for the AI and energy storage boom.

Indian manufacturer Zeon Lifesciences has secured key U.S. regulatory approvals, offering American brands a new, quality-vetted partner in a shifting market.

A Utah diagnostics firm is at the FDA's door with a point-of-care PCR system. It’s a bid to redefine testing, but giants and regulatory hurdles loom large.

A new FDA-cleared device, Livi, aims to solve post-sex discomfort. Is it a true innovation in women's health or the creation of a new market need?

With a key acquisition and a new regulatory license, Hong Kong's Payment Asia Group is consolidating the Canadian fintech market to build a powerful new payments bridge.

An AI tool just received FDA clearance to quantify Alzheimer's biomarkers in brain scans. It promises earlier answers, but raises profound questions for patients and our healthcare system.

As New Zealand reopens the door to fossil fuels, a junior explorer's uncontested bid reveals a high-stakes play at the crossroads of energy security and climate policy.

With 116% revenue growth, vape firm Charlie's Holdings unveils a bold plan for an age-gated flavored disposable, aiming to conquer a shifting FDA landscape.

FANCO's new HALEU fuel facility plan is a critical step, but it exposes the steep costs and regulatory hurdles in the race for U.S. energy independence.

Beyond beta-blockers, a new class of targeted therapies is revolutionizing hypertrophic cardiomyopathy care, sparking a fierce corporate race for market dominance.

Quoin Pharmaceuticals scores key regulatory wins for its rare skin disease drugs, offering hope where none existed. But can its cash hold out long enough?

With regulatory winds at its back in the US and EU, Cibus is pushing to commercialize its non-GMO tech. Can new leadership turn R&D into revenue before cash runs out?

With its latest FDA clearance, Distalmotion completes a strategic portfolio targeting 3M+ annual outpatient surgeries. Is its DEXTER robot the key to the ASC kingdom?

A niche software firm just unlocked the federal market in weeks, not years. Their secret weapon? An AI platform that turns a dreaded security gauntlet into a strategic advantage.

Abeona Therapeutics celebrates rising sales for its life-changing RDEB therapy, ZEVASKYN. But behind the numbers lies a story of manufacturing hurdles and mounting debt.